Table 4 Benefits and drug costs over 1-year to a practice population of 10,000 resulting from the introduction of these treatments assuming the incremental benefit of the drugs
From: Implementing guidelines in primary care: can population impact measures help?
Number Needed to Treat (NNT) | Number to be Treated in your Population (NTP) | Number of Events Prevented in your Population (NEPP) | Total drug cost (€) | Drug cost per death prevented (€) | ||
|---|---|---|---|---|---|---|
MI | ||||||
ACE-I | 69 | 53 | 0.76 | 5,292 | 6,944 | |
BB | 48 | 84 | 1.74 | 3,793 | 2,174 | |
Statin | 53 | 120 | 2.26 | 46,150 | 20,423 | |
Aspirin | 93 | 37 | 0.40 | 410 | 1,019 | |
MI + CHF | ||||||
ACE-I | 23 | 3 | 0.15 | 336 | 2,299 | |
BB | 16 | 9 | 0.55 | 406 | 739 | |
Spironolactone | 11 | 12 | 1.00 | 1,663 | 1,655 |